GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Accounts Payable & Accrued Expense for Financial Companies

BioXcel Therapeutics (FRA:BX2) Accounts Payable & Accrued Expense for Financial Companies


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Accounts Payable & Accrued Expense for Financial Companies?

Accounts Payable & Accrued Expense for Financial Companies only applies to insurance companies.


BioXcel Therapeutics (FRA:BX2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Accounts Payable & Accrued Expense for Financial Companies
Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.